


BC CANCER AGENCY EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA



Discontinued for patients will be solely responsible for verifying the doses, providing the prescriptions and standards of care.

THESE GUIDELINES ARE A COMPILATION OF PUBLISHED GUIDELINES AND CURRENT PRACTICE. ([Hotlink to references](#))
Any comments/questions – contact Dr. Kerry Savage at: KSavage@bccancer.bc.ca or Dr. Shirin Abadi at Sabadi@bccancer.bc.ca
Contact information for BCCA Centres:
Kelowna: CCSI – (250) 712-3900, Surrey: FVCC – (604) 930-4055, Vancouver: VCC – (604) 877-6000, Victoria: VICC – (250) 519-5500.

BC CANCER AGENCY

EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA

SUGGESTED DOSING FOR ANTIBIOTICS (IN ADULT PATIENTS WITH **NORMAL** RENAL FUNCTION):

Amoxicillin+Clavulanate	PO	500 mg TID
Cefepime	IV	1-2 g Q8-12H
Ceftazidime	IV	1-2 g Q8H
Ciprofloxacin	IV	400 mg Q12H
	PO	750 mg Q12H
Gentamicin/Tobramycin	IV	5-7 mg/kg IV Q24h (if CrCl > 60 mL/minute, otherwise use caution & prolong dosing interval)
Imipenem	IV	500 mg Q6H
Meropenem	IV	1 g Q8H
Piperacillin+Tazobactam	IV	3.375 g IV q6h
Ticarcillin+Clavulanate	IV	3.1 g IV q4-6h
Vancomycin	IV	Dose varies depending on patient's weight, age, and serum creatinine (goal: to achieve steady-state trough level of 10-15 mg/mL, depending on type of infection and patient-specific factors)

References¹⁻⁷:

1. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.[comment]. Clin Infect Dis 2002;34(6):730-51.
2. Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.[comment]. N Engl J Med 1999;341(5):312-8.
3. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13(1):165-76.
4. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71(11):3640-6.
5. Rolston KV. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 1999;29(3):515-21.
6. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18(16):3038-51.
7. Sanford JP. Guide to antimicrobial therapy. Dallas, Texas: Antimicrobial Therapy, Inc.; 2008.